SUNNYVALE, Calif. - 23andMe Holding Co. (NASDAQ:ME), a prominent player in the genetics and preventive health industry, has announced its return to compliance with Nasdaq's listing requirements. The company confirmed today that it has met the minimum bid price and board independence standards necessary to continue its listing on The Nasdaq Capital Market.
The compliance milestone comes after the company addressed the minimum closing bid price requirement stipulated by Nasdaq Listing Rule 5550(a)(2). Additionally, 23andMe has fulfilled the criteria for a majority independent board and various board committee requirements as per Nasdaq Listing Rule 5605. These developments ensure that 23andMe's Class A common stock will remain listed and continue trading under the ticker symbol "ME."
23andMe's achievement in regaining compliance is a critical step for the company, which focuses on consumer healthcare and biopharmaceuticals driven by human genetics. The company aims to empower individuals for a healthier future through its genetic testing services and research.
The press release also contained forward-looking statements regarding the company's expectations and projections about future events. However, it is important to note that such statements are predictions and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected.
Investors and stakeholders are reminded that forward-looking statements should not be seen as guarantees of future performance, and they are advised to refer to the company's filings with the Securities and Exchange Commission for a more detailed understanding of the risks involved.
This news is based on a press release statement from 23andMe, and it reflects the company's current position as of today. The company has not made any further comments beyond the content of the press release.
In other recent news, 23andMe has executed a 1-for-20 reverse stock split, significantly reducing the total number of Class A and Class B common shares. The biotech firm recently reported a 34% decrease in Q1 2025 revenue, dropping to $40 million, primarily due to the termination of a partnership with GSK (LON:GSK). However, the company's net loss improved, standing at $69 million compared to the previous year's $105 million. Citi has maintained a Neutral rating on 23andMe.
The company is facing potential delisting from Nasdaq due to non-compliance with corporate governance requirements after the resignation of all independent directors over strategic differences with CEO Anne Wojcicki. In product development, 23andMe launched a new report aimed at helping individuals understand their genetic predisposition to emotional eating and partnered with Mathew Knowles (NYSE:KN) to promote the benefits of genetic testing for identifying personal health risks. Additionally, its subsidiary, Lemonaid Health, introduced a new weight loss program providing access to GLP-1 medications through a monthly subscription model. These are the recent developments shaping 23andMe's trajectory.
InvestingPro Insights
While 23andMe has successfully regained compliance with Nasdaq's listing requirements, recent financial data from InvestingPro paints a challenging picture for the company. The genetics firm's market capitalization stands at $125.83 million, reflecting its current position in the market.
InvestingPro Tips highlight that 23andMe is "quickly burning through cash" and "not profitable over the last twelve months." These insights align with the company's financial struggles, which likely contributed to its previous non-compliance with Nasdaq's minimum bid price requirement.
The company's revenue for the last twelve months as of Q1 2023 was $199.19 million, with a concerning revenue growth of -32.67% over the same period. This decline in revenue, coupled with an operating income margin of -128.25%, underscores the financial challenges 23andMe faces as it strives to maintain its market position.
Despite these hurdles, an InvestingPro Tip notes that 23andMe "holds more cash than debt on its balance sheet," which could provide some financial flexibility as the company works to improve its performance.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for 23andMe, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.